$2.270
+0.041 (+1.79%)收盤時
- High
- 2.360
- Open
- 2.240
- VWAP
- 2.28
- Vol
- 4.08M
- Mkt Cap
- 392.15M
- Low
- 2.200
- Amount
- 9.28M
- EV/EBITDA, TTM
- 1.45
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
估值指標
事件時間軸
資訊
8.505-13NewsfilterACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
- 8.505-13Newsfilter
Alumis Stockholders Approve Merger with ACELYRIN
8.505-13GlobenewswireAlumis Stockholders Approve Merger with ACELYRIN
- 8.505-06Newsfilter
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis
- 8.505-01Newsfilter
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
SLRN FAQ — answered by Alphio AI
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。